Visalytics
Visalytics
approved EB-2 (NIW)

CEO

Artificial Intelligence · Syria · 2025-06-25

Processing Time
200 days
Decision Date
2025-06-25
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to lead scientific initiatives building machine learning models that accelerate the drug discovery process, specifically focusing on simulating molecular interactions to design personalized cancer treatments. Her work aims to address bottlenecks in drug development by blending multi-omics data with predictive AI systems to reduce costs and increase precision.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The endeavor was found to have substantial merit and national importance due to its potential to reshape healthcare and drug discovery through scalable AI solutions.

2 Well-positioned to Advance the Endeavor Met

The petitioner is well-positioned based on her role as a CEO, her extensive publication record with high citation counts, and her history of successful commercial ventures in AI.

3 On Balance, Beneficial to Waive Job Offer/Labor Cert Met

It was determined beneficial to the U.S. to waive the requirements given the life-saving potential and economic efficiency of her AI-driven drug development platforms.

Why This Petition Was Approved

The petition was approved based on the petitioner's significant scholarly impact, including 5 journal articles, 31 conference papers, and over 3,680 citations, placing her in the top 10-20% of her field. Additionally, she holds one U.S. patent and two applications, and demonstrated commercial success through the acquisition of her AI venture by a global pharmaceutical company. All three Dhanasar prongs were satisfied through her leadership roles and technical contributions.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Patents
Conference Presentations
Original Contributions
Commercial Success

Similar Cases

Consultant

Engineering · India

WeGreened EB-2 (NIW) approved
New Jersey 45 days 2025-01-16
The petitioner proposes to continue research on developing advanced machine learning, artificial intelligence, and language modeling frameworks by integrating data-driven methods with domain knowledge. This work aims to address key challenges in drug development and healthcare, specifically focusing on accelerating drug discovery, optimizing clinical trials, and enhancing manufacturing efficiency.
View Case

Postdoctoral Researcher

Pharmaceuticals · Bangladesh

WeGreened EB-2 (NIW) approved
Illinois 535 days 2026-01-16
The petitioner proposes to continue research in clinical pharmaceutical sciences, specifically focusing on understanding cancer development at the molecular level. The work involves investigating mechanisms such as genome instability and replication stress to identify actionable molecular targets for cost-conscious therapeutic strategies.
View Case

Others

Biotechnology · China

WeGreened EB-2 (NIW) approved
Georgia 67 days 2025-05-14
The petitioner proposes to develop advanced artificial intelligence models and algorithms to improve early disease diagnosis and predict patient responses to new drugs and combination therapies. This work focuses on enhancing diagnostic precision and treatment effectiveness to accelerate drug discovery and optimize healthcare outcomes. The endeavor specifically aims to benefit vulnerable populations, including infants and the elderly, through optimized medical interventions.
View Case

Physician

Biotechnology · China

WeGreened EB-2 (NIW) approved
27 days 2025-03-13
The petitioner proposes to focus on repurposing existing drugs for cancer treatment by leveraging advanced computational methods and bioinformatics tools. This work aims to enhance therapeutic options, improve patient outcomes, and significantly reduce the time and cost associated with traditional drug development.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Artificial Intelligence cases More cases from Syria

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-06-25.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 200 days
Criteria Met 3 / 3
Evidence Types 6

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,895
Success Rate 54.2%
Sustained 2,112
Dismissed 1,687

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in Syria All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist